نتائج البحث - "Glucagon-Like Peptide-1 Receptor"

1

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

المؤلفون: Enrique Z. Fisman, Alexander Tenenbaum

المصدر: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-5 (2021)
Cardiovascular Diabetology

مصطلحات موضوعية: Blood Glucose, Glucagon-like peptide-1, Agonist, endocrine system, medicine.medical_specialty, Dual GLP-1/GIP receptor agonist, Glucose-dependent insulinotropic polypeptide, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Incretin, Gastric Inhibitory Polypeptide, Tirzepatide, Incretins, Glucagon-Like Peptide-1 Receptor, Receptors, Gastrointestinal Hormone, Internal medicine, Type 2 diabetes mellitus, Insulin Secretion, medicine, Animals, Humans, Hypoglycemic Agents, Insulin, Diseases of the circulatory (Cardiovascular) system, Obesity, Receptor, Triglycerides, Glucagon-like peptide 1 receptor, Metabolic Syndrome, Gastric emptying, business.industry, digestive, oral, and skin physiology, Glucagon secretion, Lipids, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, RC666-701, Commentary, Cardiology and Cardiovascular Medicine, business, Biomarkers, hormones, hormone substitutes, and hormone antagonists, Hormone

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b4eff864d23c45c53fad3ee5fd6c7bTest
https://doi.org/10.1186/s12933-021-01412-5Test

2

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

المؤلفون: Antonio Ceriello, Miriam Longo, Katherine Esposito, Giuseppe Bellastella, Paola Caruso, Dario Giugliano, Lorenzo Scappaticcio, Maria Ida Maiorino, Paolo Chiodini

المساهمون: Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., Esposito, K.

المصدر: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Cardiovascular Diabetology

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Cardiovascular outcome trials, Risk Factors, Efpeglenatide, Cause of Death, Original Investigation, Clinical Trials as Topic, Incidence, Hazard ratio, Cardiorenal outcome, Middle Aged, GLP-1RA, Hospitalization, Treatment Outcome, Cardiovascular Diseases, Female, Kidney Diseases, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Oral semaglutide, Lixisenatide, Placebo, Incretins, Risk Assessment, Glucagon-Like Peptide-1 Receptor, Albiglutide, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Diseases of the circulatory (Cardiovascular) system, Dulaglutide, Aged, Cardio-Renal Syndrome, business.industry, Cardiorenal outcomes, Semaglutide, Liraglutide, medicine.disease, Confidence interval, Cardiovascular outcome trial, Diabetes Mellitus, Type 2, RC666-701, Heart failure, Exenatide, business, Mace

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9e3d37fb03d26f466c29937ba81e9fTest
https://doi.org/10.1186/s12933-021-01366-8Test

3

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

المصدر: Dagenais, G R, Rydén, L, Leiter, L A, Lakshmanan, M, Dyal, L, Probstfield, J L, Atisso, C M, Shaw, J E, Conget, I, Cushman, W C, Lopez-Jaramillo, P, Lanas, F, Munoz, E G C, Pirags, V, Pogosova, N, Basile, J, Sheu, W H H, Temelkova-Kurktschiev, T, Raubenheimer, P J, Keltai, M, Hall, S, Pais, P, Colhoun, H M, Riddle, M C & Gerstein, H C 2020, ' Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail : a post hoc analysis ', Cardiovascular diabetology, vol. 19, no. 1, pp. 199 . https://doi.org/10.1186/s12933-020-01179-1Test
Cardiovascular Diabetology

مصطلحات موضوعية: Male, medicine.medical_specialty, Time Factors, Recombinant Fusion Proteins, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Type 2 diabetes, Placebo, Incretins, Risk Assessment, Glucagon-Like Peptide-1 Receptor, law.invention, Double-Blind Method, Randomized controlled trial, law, Internal medicine, medicine, Humans, Hypoglycemic Agents, Uncategorized, Original Investigation, Aged, Unstable angina, business.industry, Incidence (epidemiology), Hazard ratio, Middle Aged, Cardiovascular disease, medicine.disease, Glucagon like peptide-1 receptor agonists, Immunoglobulin Fc Fragments, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Heart Disease Risk Factors, Female, Dulaglutide, Cardiology and Cardiovascular Medicine, business, Mace, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e03a38716bcec2e154f3ddff98a2ece2Test
https://doi.org/10.1186/s12933-020-01179-1Test

4

From glucose lowering agents to disease/diabetes modifying drugs: a 'SIMPLE' approach for the treatment of type 2 diabetes

المؤلفون: Antonio Ceriello, Meir Schechter, Lawrence A. Leiter, Ralph A. DeFronzo, Itamar Raz, Stefano Del Prato, Ofri Mosenzon

المصدر: Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)

مصطلحات موضوعية: Blood Glucose, medicine.medical_specialty, Glycated Hemoglobin A, Combination therapy, Endocrinology, Diabetes and Metabolism, Clinical Decision-Making, Population, Review, Glycemic Control, Type 2 diabetes, Disease, Hypoglycemia, Clinical approach, Lower risk, Incretins, Glucagon-Like Peptide-1 Receptor, Decision Support Techniques, Terminology as Topic, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Diseases of the circulatory (Cardiovascular) system, Humans, Hypoglycemic Agents, Intensive care medicine, education, Sodium-Glucose Transporter 2 Inhibitors, Glycated Hemoglobin, education.field_of_study, Primary Health Care, business.industry, Patient Selection, medicine.disease, Type 2 Diabetes, Metformin, Treatment Outcome, Diabetes Mellitus, Type 2, RC666-701, Diabetes/Disease Modifying Drugs (DMDs), Biomarkers, Cardiology and Cardiovascular Medicine, business, Type 2, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d79c8e92b0cc27fb1720ba9195c4d12Test
https://doi.org/10.1186/s12933-021-01281-yTest

5

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

المؤلفون: Jan Škrha, Ilze Konrāde, Guntram Schernthaner, Fahim Ebrahimi, Alexander Ametov, Peter Fasching, Naim Shehadeh, Nebojsa Lalic, Péter Kempler, Žydrūnė Visockienė, Anna V. Bazarova, Emil Martinka, Andrej Janež, Tsvetalina Tankova, Cristian Serafinceanu, Dario Rahelić, Boris Mankovsky

المصدر: Cardiovascular diabetology [electronic resource], BioMed Central, 2020, vol. 19, iss. 1, art. no. 185, p. 1-17
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-17 (2020)
Cardiovascular Diabetology

مصطلحات موضوعية: Blood Glucose, lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Clinical Decision-Making, Glycemic Control, Type 2 diabetes, Disease, Global Health, Incretins, Risk Assessment, Glucose lowering drugs, Glucagon-Like Peptide-1 Receptor, cardiorenal protection, clinical inertia, glucose lowering drugs, type 2 diabetes, Risk Factors, Internal medicine, Diabetes mellitus, medicine, Humans, Practice Patterns, Physicians', Medical prescription, Sodium-Glucose Transporter 2 Inhibitors, Angiology, Glucose lowering, Evidence-Based Medicine, High risk patients, business.industry, Cardiorenal protection, Protective Factors, medicine.disease, Clinical inertia, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, lcsh:RC666-701, Heart failure, Practice Guidelines as Topic, Commentary, Kidney Diseases, Cardiology and Cardiovascular Medicine, business, Biomarkers